0000950170-24-028784.txt : 20240308 0000950170-24-028784.hdr.sgml : 20240308 20240308172710 ACCESSION NUMBER: 0000950170-24-028784 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240308 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240308 DATE AS OF CHANGE: 20240308 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Xenon Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001582313 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980661854 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36687 FILM NUMBER: 24735697 BUSINESS ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G 48W BUSINESS PHONE: (604) 484-3300 MAIL ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G 48W 8-K 1 xene-20240308.htm 8-K 8-K
0001582313false00015823132024-03-082024-03-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 8, 2024

XENON PHARMACEUTICALS INC.

(Exact name of Registrant as Specified in Its Charter)

Canada

001-36687

98-0661854

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

200-3650 Gilmore Way

Burnaby, British Columbia, Canada

V5G 4W8

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (604) 484-3300

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange on which registered

Common Shares, without par value

 

XENE

 

The Nasdaq Stock Market LLC
(The Nasdaq Global Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01

Other Events

On March 8, 2024, Xenon Pharmaceuticals Inc. announced the meeting, record date and certain other information relating to its 2024 annual meeting of shareholders pursuant to a filing submitted to the System for Electronic Document Analysis and Retrieval in Canada.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits.

Pursuant to the rules and regulations of the Securities and Exchange Commission, the attached exhibit is deemed to have been furnished to, but not filed with, the Securities and Exchange Commission:

 

Exhibit Number

Description

99.1

SEDAR+ filing submitted March 8, 2024.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 

XENON PHARMACEUTICALS INC.

Date: March 8, 2024

By:

/s/ Sherry Aulin

Sherry Aulin

Chief Financial Officer

 

 

 EX-99.1 2 xene-ex99_1.htm EX-99.1 EX-99.1

img189401473_0.jpg 

Exhibit 99.1

 

 

March 7, 2024

 

Alberta Securities Commission

British Columbia Securities Commission

Ontario Securities Commission

RE: Xenon Pharmaceuticals Inc.

Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of the following information in connection with its Annual Meeting of Shareholders:

 

Date of meeting:

June 4, 2024

Record date for notice:

April 5, 2024

Record date for voting:

April 5, 2024

Beneficial ownership determination date:

April 5, 2024

Securities entitled to notice:

Common Shares

Securities entitled to vote:

Common Shares

Issuer mailing directly to non-objecting beneficial owners:

No

Issuer will pay for objecting beneficial owner material distribution:

Yes

Issuer using notice-and-access for registered investors:

No

Issuer using notice-and-access for non-registered investors:

No

Notice-and-access stratification criteria:

N/A

Thank you,

/s/ Tamara Cajuste

Tamara Cajuste

Senior Relationship Manager

Equiniti Trust Company, LLC.

Tel: 347-939-9659

Email: Tamara.Cajuste@equiniti.com

 

 GRAPHIC 3 img189401473_0.jpg GRAPHIC begin 644 img189401473_0.jpg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end EX-101.SCH 4 xene-20240308.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink Pre Commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address State Or Province Entity Address, State or Province Trading Symbol Trading Symbol Soliciting Material Soliciting Material Entity Address City Or Town Entity Address, City or Town Written Communications Written Communications Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Address Postal Zip Code Entity Address, Postal Zip Code Entity Incorporation State Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number City Area Code City Area Code Pre Commencement Tender Offer Pre-commencement Tender Offer Cover [Abstract] Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Entity File Number Entity File Number Entity Address Address Line1 Entity Address, Address Line One Security12b Title Title of 12(b) Security Entity Address Country Entity Address, Country Document Type Document Type XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Mar. 08, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 08, 2024
Entity Registrant Name XENON PHARMACEUTICALS INC.
Entity Central Index Key 0001582313
Entity Emerging Growth Company false
Entity File Number 001-36687
Entity Incorporation, State or Country Code Z4
Entity Tax Identification Number 98-0661854
Entity Address, Address Line One 200-3650 Gilmore Way
Entity Address, City or Town Burnaby
Entity Address, State or Province BC
Entity Address, Country CA
Entity Address, Postal Zip Code V5G 4W8
City Area Code 604
Local Phone Number 484-3300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, without par value
Trading Symbol XENE
Security Exchange Name NASDAQ
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( &2+:%@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !DBVA88%"KV>\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M:L,P#(=?9?B>R''V#Y/ZLM+3!H,5-G8SMMJ:Q8FQ-9*^_9RL31G; ^QHZ>=/ MGT"-"=+T$9]C'S"2PW0U^K9+TH05.Q %"9#, ;U.94YTN;GKH]>4GW$/09L/ MO4<0G-^"1])6DX8)6(2%R%1CC301-?7QA+=FP8?/V,XP:P!;]-A1@JJL@*EI M8CB.;0,7P 0CC#Y]%] NQ+GZ)W;N #LEQ^26U# ,Y5#/N;Q#!6]/CR_SNH7K M$NG.8/Z5G*1CP!4[3WZM'];;#5."B^N"UP6_WPHAQ9WD-^^3ZP^_B[#OK=NY M?VQ\%E0-_+H+]0502P,$% @ 9(MH6)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" !DBVA8U)W)76X$ H$0 & 'AL+W=OC##*U +##4., MW_YZ4,';Q<8W"DC_^='3\^\9!QLAO^<18XI\)'&:#XU(J>S6-/,@8@G-KT3& M4OAE)61"%9S*M9EGDM&P#$IBT[&LOIE0GAJC07EM)D<#4:B8IVPF25XD"97; M.Q:+S="PC<.%5[Z.E+Y@C@897;,Y4U^RF80SLU()><+2G(N42+8:&IY]>^?T M=$!YQU?.-OG1,=&OLA3BNSZ9A$/#TD0L9H'2$A2^WIG/XE@K <>_>U&C>J8. M/#X^J#^4+P\OLZ0Y\T7\QD,5#0W7("%;T2)6KV+SB>U?J 0,1)R7GV2SN[?; M-4A0Y$HD^V @2'BZ^Z8?^T05%+>4T5' RDV1.J[04T? ME*]:1@,<3_6HS)6$7SG$J=&]" I(LB(T#(B^U0SV M@G<[0>>$X#.55\1R+XAC.=W_AYO 5@$Z%:!3ZG5.Z/GBG4GRM[?,E80A_*>) M:*?0;5;0=7V;9S1@0P,*-V?RG1FC7W^Q^]8?"%^GXNM@ZG4"%]N,-<'AX>[E M9P2B6T%T414/",*2XB&FZR8*/'Y%XYPA'+V*HW=>,F9,/ORPFOO0U^= ^I!#26.8B2'[()_9M@D35[(LR^ZY3L?N(%ANA>6>@S5. MF%SS=$T>(5Y%Q!=)1M-&.%ROK=YN*JZ;<[@>>,S(M$B63#:QX!J0I\M.O^]> M(SRV5=NI=0[1) V$S(0L3?2"S!5, B(D9*R D84!%F%CZ;6H?\,F@GWD^?8Y MD OZ028AE!I?\: D19+8(GGC7EK]ONWV4,+:]&W4LP^$7AB"8^<7AP/R!/>1 ME[0Y=[@DK%-@G'L6>>1Q(B0C;W2+L=8-P,8M_$=67Y_!6"_$IKE_XG)WA4SI M$D6KVX*-^_J/:%4=SJ1XYVG0G$=<\\['T.I.8>,&_U/6=C.C$0A7\CT,J&X/ M]EG]H0*:B5R!!7_CV>G9BBM^[3V2[IN+T=5]P<;MO"PJ#];=IV%P@;Z%SLRZ M$]BX=3^) +(RBT2*66Z+2-?M7G8ZEH41U3W Q@W\37*E6*J[45*D>R?+&ZEP MH;:NY-1=P,%]>BYB'G"E6^4SS#C):=RX;L556GEJPW=P=YY)=AE >AA,^=UB M%=:+L*Q^6:V:QZ]%KY7L:'6/N_)/9),\+X"L%1"7;06LW=W![7C!%2PNQ(K8 MSF_+W\F_]_YL8C*/ M]KWZ/P38-,#R-"6QEO%DN7/Z MZZ>S;"=I=67=A['-HN M6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2 MK"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP( M&K XU7=>&18/QA<0&>7= MJ?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N- M9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W] MK;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LU MF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ> MDO:C_S=7^2V,D_'T7!S1JP,Z6PEY7>>9 ]IV03NA1.XJRY/K%.?7A M'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?#$T%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/ M9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@> MF*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%' M, ; 4/2='@//GL?)=-[*CG_5U/\!%!+ P04 " !DBVA8EXJ[', 3 M @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/ MV!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%" MKM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0 MT^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( &2+:%@< M.&7J/P$ #P" / >&PO=V]R:V)O;VLN>&ULC5'+;L) #/R5U7Y $U"+ M5$2XE#Z0JA:5BON2=8C%/B*O RU?7R=15*1>>O)Z;(UG9A?G2,=]C$?UY5U( MA:Z9FWF6I;(&;])-;"#(I(KD#4M+ARPU!,:F&H"]RZ9Y/LN\P:"7BY%K0]EU M$QE*QA@$[( =PCG]SKM6G3#A'AWR=Z'[MP.M/ ;T> %;Z%RK5,?S2R2\Q,#& M;4N*SA5Z,@QV0(SE'WC;B?PT^]0C;/8?1H04>I8+8864N-_H^8UH/($L#UW+ M\0D= ZT,PS/%ML%PZ&C$179EH\]AK$.(<_I/C+&JL(15+%L/@8<<"5PG,*0: MFZ15,!X*/:XH$ZQZ#"PAJ748J&2WEYIK=WDWM)J'7N0;#W\!J-'[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):B MJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% M @ 9(MH6&60>9(9 0 SP, !, !;0V]N=&5N=%]4>7!E&ULK9-- M3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/ MGI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3 M>*HH>Y3KU3.T.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+ES MT&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JH MO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-( M9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX: M?^:+X3]>?P%02P$"% ,4 " !DBVA8!T%-8H$ "Q $ M @ $ 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( &2+:%A@4*O9 M[P "L" 1 " :\ !D;V-0&UL4$L! A0#% @ 9(MH6-2=R5UN! *!$ M !@ ("!#@@ 'AL+W=O,1 !X;"]? M7!E&UL4$L% 3!@ ) D /@( !(4 $! end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports xene-20240308.htm xene-20240308.xsd http://xbrl.sec.gov/dei/2023 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "xene-20240308.htm": { "nsprefix": "xene", "nsuri": "http://www.xenon-pharma.com/20240308", "dts": { "inline": { "local": [ "xene-20240308.htm" ] }, "schema": { "local": [ "xene-20240308.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_52a0e847-b597-46a0-9bf1-7db11a16cc27", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "xene-20240308.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_52a0e847-b597-46a0-9bf1-7db11a16cc27", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "xene-20240308.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Country", "terseLabel": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security12b Title", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.xenon-pharma.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0000950170-24-028784-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-028784-xbrl.zip M4$L#!!0 ( &2+:%@N4Q$+(A, +^O 1 >&5N92TR,#(T,#,P."YH M=&WM/?M3&SF3O^]?H2/U;4@=LN?],"1?$'DG]5'>K)1W]>]@+R14D:1!'[]^J->4M@8C' M(H@NW[\][C3;[;?__O#;43=#, 2-TO=[W2SK-^KUZ^OKVK5>BY/+NNJZ;GTH M8?8*H,;02T(1W,#*CSFDIBA6O7@X 9I-!34+T&P<-)@8P#BT7@^B-&,1APH^ M#**?#X#+QQY+;\"']^ G\)-/*]!@.*M=50X#0>''Q_.O%7@41R>#'B0!G_Z: MR))Z-NI#'0%I5$#>C"H-IHT),5#K/[Y][? N]!B]B[J .]1/@=8A@_"F_[$'&B&R#PC^#X.K]7C..,H@R>H$\W".\ M^/1^+X-A5L_5HBX;K9>M'GFQ&)$T&X5(^1Y++H.H0=@@B_\CZ/7C!/F8'?:9 MD#K8($Y_>+B7]RJ"J^HE$:3]D(VD7 $^/0J&#=DV),6?@1 0Y7_>"AX)Q/N] MSW\SRP'=MFQJN"[^9ZN"NHP!=2T?N.;I7'7%'HE83_8"0:,5(=JC)J*3L+ = M"1C^":,2Q6%V#CXB_[>I,04*1NUF$)=SU>I+3Q59:K%N6;O?5!08DU' MTU7]J#XQM.DC]53=U353IR88!C5\IE+/\+!ESGS+0#MB>'Q\I,<]B 3^RSZ' M['*Y$?HL3.'>X.J3)$W AP1M)*0?CJ1):*2Y!F)')#<1#:G([_=2Y&4HU3'_ MKIO(<4A=HY4ZU8:I0+G(FQ]O,_^8QH,D_Y2;O$:)3$Z919$I7X6<@=6G0,C/ M?@ )R8<-4Y6RV?YSDEUW7_Y0?379>A\)%HOJ$QJD)/O$,O@@4::*CMI?\L<]Z M03AJ7 0]2,D)7)/SN,>B"M:+LRSN-91#B01E87 9-3A2%1(YH+3/HFHH/ [C MI%'U?-T-,J#XG$.CGP"]3EA_;#C&O-ZQZ^M 9-V&'V2T-%C8(QHIV2>2HC^3 M$&I%ALI(5=\^1([718W9B%K/A>AU('(IQ/CA+HO[]I'W1^D0Z%\<7K<[C MR:"\"B)T6LWOY^V+=JM#CD\^D=:/YA_')U]:I'GZ[5N[TVF?GKQTRLRU4C,H M\]=QYX_VR9>+TY,#\JG6K!%-,0VWHL86#'"FZI84#L'/&H;RKQL;5I+\83/F M/E*[2ZMYVW9I.$NX)$=9CF*]]FZN$5J?O7LL1;95U3^?GG\CT^3W$6WOS7!D M+4V8H&N4 T-WS3,]ZG%-H"/(3.CL]OW@)T]WKY\G9($D'+,I( M%I,.<)GV(:I.XH2HYKYX1V*?9%V0CP9)D 789FO(NRRZ!'+,,_E8=75CQ\MU MHJXLB;H,]"5'SD'FP _S:#+# M>U \!4RA^U3S?48-VU.I8]L>573FJN 9KF#*NKR'LSRUTBH2+GND2*.^WPN& M64/@-[2'O73E:U2P$1TA5RA$VR$YWUC"N\0Y(#*!-,?QV$WV+\L8W7:ES!<756)BDSY.5P&J5R$R$[PR5IU M8R[RLWCXHW5R>D+._C@^_W;<;'V_:#>/OW9(^Z19>S(/?>FQ+R%_SY1AR<=B MRR3Q4HCNMX8,W1$I3\4,6,D182GI]('+Q+L@043:64J:78838/)N%4ZM..!= M[+3EXBP9L!*2=OYPBD.(*EZOPK2P M"--2-ZOT2"*%$ M!55TI^LU7?O78;YV.^NYL?#SHWJ6W!U-N?ZDJKD23N7&-2)+O038ST;^/Y5? M3.'RW2%<09(%G(4E5"$?-ZJ8E.M>BEHL?#V=59T^/W/5 ]51<895'0V=7,/# MOPR3:IIJ,]U5N*JO[.06\W,[XG&"T4->'M#)4&R:\2#*DE$S%I,NKRQ9:("X M9$D_B:]X ;46=W=F=H%%3+#YSBN*DGCA#/<S[95SH@7#/P)!ODG**H5+S9LNWGQ17=/HG)J=W&S<: M+TH2FG&O%Z2R3)5(DTX*2[ CT@21VN<=TNKUPW@$R6O3C\F)@)S$M:G,?\C/ MUFK:(QWM;7:LI\5W4U&;1='?WZB6FS#4$]?&![9J.*0QMK>QH MXI^GR45\ODTV"@PJ^R:DJA-S5 9PZMF)3UV:. US1/>ZO5SV*3-A]]I0ILHTS9Z4T M634)Y?EGI2:GH.FSU?2)R'C>W/PB&?=5?9HMG)$=R_"%J\IM7)9"#%80N7^6S5V43&$!*3-3L7;=,17*('[C!$E)&4-7)('F/B1%8[9 M 0E\4A3NH]A](N"E 2R"8'2G\6H +U!F+$( MXD$:CDC*LB#U1_F;Y0NQAX@6:V7E%ICDMJ9T@.V@9D6CZID?A]BY?$\FV *Y MSIJ2_12 ?($($@R%VA&^.RCVUQS7M%HQW-6V8*S74K[4.L.:]4 5H6O5%BLB M7'G5YD[DJMCF_=@5M>Y^4&>;"R^%K5ECQYMZVX'+&,CW-NF,>FC*WQZD+$II MBGZ./\LO=#3/%US3J6NX"C54F5@2GDD=QS-\Q_!MC!16]0O_2H(,!5;6+PRB M(X]!@J88:F8'V!^^]O7-LP#M>3+7T)(K$"K4I.(;_'647Z8QL, MSP=H80S-+ WHG8V%E8C9F87UF@67,]4S3 P7 M-5NGAB)57%:G:MQ0?,_P5(NM7)W:05^,H]A$E]]P3D$G(-S9A"VT";=L(KV2 M3_<-@FHPJFIC-F%BA_&-13"46@&Y,PHOT"AXG'NF"0;ECNU2PS9]ZJB.01W? M]S7+02WW5UYH/4M ^@GR)+C\- _I[B>GO@_)SCALH7% =E$^QJ^YGH-J"*KM M>^\6,Q4%[,Y8O$1C@>&#JP*GMNFAX@O-HBX8/F6^+GPN#-52C#4;BW::#B#9 MF8S79C)TH,8^7\QDE+!/:C*>;EGS^7)V8S%>D42#!,0$KVY.GLG->YE40_XT M'LI1K2\EM5H"RGD@_Z0^],Q<\D7#7"2EI2DU]VFV3TVFRL=.>IUA7YRM6W^9 M);D7\M#JX@@=WB4\9&FZ7"G'3!*1-W[^H^C/0JPGVP#PBF4D87GIQ9&7U#\4 M/L[^_$*GG9C\8F)R4AY-DEL2J'P0G/.P6?SF=F)\=(!14S=LYJ7_^*1UK-/Y M/"-8X!R8J:/O9C/N4<-W51DL"&JYCFGYZ/R;FKERNK'P8$:JYN53POH\6AF# MH!!TNBR!](!"C@FY8N$ E@P+'E,T^=)-QW:+)]--CVF:2\'R4=14 M1X:QOJ!@&HJP7<<#15]5/,LIJ)A\UB>;/UHGK9W\K8;<-HB@XNF6T'03+20: M1Q0G@[H&9U0 UTR=<4VW5UZGK2QD%5WGY[?=/Q &GRZ[PV6F_X6AX@E+!?N' M=+*8_R3?6/(3,O+U:W,#)9NW$CMC.+D;N#\VJ"]A[+&P'-66E#@_7RZ@'0F9 MK0'BC0C/:WEPF#_1"8+\B(H[A39!2G" @&R[E"[V91)?9UV9].G+XAN6$@%^ M$!4'NQ6+RXHYY3*<+* K$DB: M1[4%3\&]V[;,*=V^/M9Z[4Y:X[4RNS6#<8\L4UXJA>PQ-%Q"4.&8(%/()O6$ M+V_&T9FNZ*ZOZLYZ-CU52'[)<6P6**X]>[PL>5;..K]F^6S[#YB7 S0J4VU5 M<*\>L(N6"$+@&5JB*,XSFH,4K!7F6L[B#24I(WE,-UR*%LZ]->MS]4<;\XN.-'F2ZNT!J$]08NW_,#V%(19 4@BZ3](-> M=%A=[">?'MZ[HNQ_!VD6^*.J@QR*HG(^C^<^SZ;-9=GB(4QU+UOW)G?49Y=0 M)(8P&,7!-5AXS49IN:HP3NAQ&2O(.$97N1\19S,Y8KD"A5O&3%CHB M+(,><6J*.B__D8\)G2-I1'/LYM!B?#-!#C_>P$/3^-:2JCA/L26OTYBZ(+AD M1/_(:R]S\*UPI$\CF=^XO4+B@/R0]R"3L_P>9 Z#7#Q2N5&YADYNA'XLESXQ MNJ4] .G2'J##RU'3B+PJ T$$X2A4#./Z.*=U$-U<2XR0(Y2M M#M!)+IN33F\J<^I=9",DDY4AK-KDDPZ\GBQ:S_<$Y0'^*)5*(#WSEO3GDSC" MB+*ZX(,<1RP7!F$4$A% I># ML"SONY^&+>2F3&S<'G)[4.P0S3+&NVC=H:"F3"<+0(G+[7V770'Q "+B#Y(H M2+OYUP?$&V1Y$@?G"/Q&IF4.%NSU;K7:MD5 +S(N\!C_>9F@PR!H*8I%)@N#6YKJ!3R2L:R$+(]U$+I -(0(*0]?]6ZUUL]YL@J%QGDJPQXMMI_7I M^/P_[X=K$\'FK8_$7IE4/\8[V*Q,JV/G7SVO2&\/39HQ8D?.&/J ;9GA9SP_ MZO 3RUAQR<(^X+PE1.E%!E'N1K8C*?'DQ\?SKT24B86)@H G3B)MEU?YJEWF MQZU?W3G=:.KBR\PEK5]^56:WUO5,:UVKF)^M.N*NT_YR%OBRX MD0WE#F()T(4$!A&^DS?'!EDW3A!=42LVWCS?.5J_WCSV0D\*,\S:@WLU'[J- MU*AI#SZVQIN>%W?,3&FM)2 I9B]ERM'94\.19[J(9Y.G:<^GQ);=2K018F"C M\LG[/6WO-1-FX76G!>YQ?T3NX+ETN!<($<)+8M!.C7?$V!'C:0\<>B[K]'K( M_@D=T :93#3OQ'*M.OI*W-&/H\;:!./N\0?:_4T/KX!B];1..AC/)R-R/ B# MI58D=Q9N"S1X1XP7[9DO'#KM1&4\+[RS7"]?67?$>-'$V%FNI0H6N@'XY+;^ MNKB4,5ERZ>0ICKM\XCV7N]7^%[HNO>!J_U'=B\7HPV]']6[6"S_\/U!+ P04 M " !DBVA8@Q.5C)X) "S=P $0 'AE;F4M,C R-# S,#@N>'-D[5UM M;]LX$OZ^OX*G_=+B5I;M--O&J+/P)>W!N+0)DA2[N,.AD"7:%E8F?924V/]^ MAY+HB!(E.W9"R:?V0Z-(Y,-G9O@R'+[DXV^KA8\>, L\2H9&K],U$"8.=3TR M&QK?[LS1W<5X;/QV_M/'OYDFNOP\_HJ^XD/3(&(8O;G[\A;] M\8_;*W3GS/'"1I?4B1:8A,A$\S!<#BSK\?&QXTX]$E _"J&XH./0A85,,P6_ M8-CF[]&E'6(TZ'?[[\SNB=G]<-][/^B?#MZ==/J]L_=_[W8'W6XF&UVNF3>; MA^B-\Q;Q7% V(=CWU^BS1VSB>+:/[D2AOZ Q<3IHY/OHEN<*T"T.,'O ;B?! M7 7N($AD"&TVP^%7>X&#I>W@H9&19(4))>9R;K.%'0O"2^Z>=#\8R Y#YDVB M$'^F;'&)IW;DAT,C(O^+;-^;>M@%'?N8*T=*D/D,1B'! )-HT=\4NIHPOT/9 MC!?4M? JQ"3P)CXV>3+,8M4%9I];,,D.@DB,'T_2[-V>]<>7J\1.(K'OD3]E M^9Z*ZYY8_//$#K!('@7FS+:7FQQ3.YC$J=,/G.2)2.QB3Y8BP$YG1A\L^" E MY!_=4"5Q]]1*/F:3>A6$H9J%8/H-83#7SO9+V1@4]_ILI.)K\E=GKFR>]#H 9B*AKG%I ZS 2PK)[D=A4 MBWU)"+/RTD_+RE76@YU*#,IJ''\P^4-EF85Z^KQ"E8W"PGX8B#>5%-1MZHF" M30@-XW+Y*_%RN?3(E"9OX!VWT(!1']^OEQCQAV^WX]T:@A7:*TKH8FWQ;-8M M_/==].KBYXBXGTCHA>LQ% H G(V!/.AX=D\NN JV+H9!PHOEZG7Y/QA",J/) MYM$F+DK04 ;NHY4'R<%' 7:OR7G\O&30]Y-$B5?P(LV<)JG(Z-B^$_G/S_=$ MJS1;^E+83+:D:'"QBOVT!\J;^A9/=5DZ[@8'W_S,_SR_8;A"[H A3BQ)S .@@BS>\Z 74^G> ,>LQT:.V6Q M]%!/S#=R76@]P1VT'GS-;AA]\)+Q-D^[,KDFRO?,YB[MW7HQH;Z"H_Q=$RGP M23T'.@,R^P)*8>"F*I@I$M5AY@MXO&;W])%LLW FI2:BOS,OA+;+VT9$O&0H M#A0TU>FT:O,"VBVS_3&TV=6_\+I4E_ET6DG>VZNQ"P1@,I(HZ6NTF"A[I.KT M6DG?XID7@,Y(/%\KY9I+IHFB&/MNH %3&/Y7"YH!&UG7>3QXK&LDE2BW>>C%Y; M7?,TF6:OAXBSA9,\DR_9(*1?4()05*]C1*BH$2D,:RS>I<'^5BO&=/+3\! M(8'4;-Y9?6LF7Q+ >IE.A^/Q/HRS M9M O@C(*>5AS2,%0C(8 KO'\%2VA!B%*HJN'&0- D8R*$MBCD4=AG!J%DL/* MA]GF"0MQL*:35QA"HP3*B/F>^M_L+$C $*#%>]$:SS]K@CJ$*%\,>!D/*H%$ M@(DXZ'&(4N5':1>H/BH:2S=M#+/+NZM:>JXWD2QWCUNG$(V:R*]3$N7YM[J9!L3;'8UXK"ZA)' M6I+#W,H!"1* M,%$*>B2R*/R'&@225IWW-,<& W&0QK+-*EP?Y?SR^6%5GN-HBU7L3UI1M[4R M5^P$>)D)IO@90QZ%'%6SRZPTZ)IH&9@[[02E4"UG3RE2M4KR]"=M_*H9%&CM%4KLJHXHZ$1TS>3F0S M1Q0-CUM*3U-8#H4IT#(T$Z6EV:>,+G8\#B,8T&=LG2G;AZ1#H%W.U0AAMFXN MJ5,0Y6D;P;RX)Z-.JN5G< 3?DHT-C:DHQ9,YRCJ2VQ!0)_W*\SJ"?/DB>OV: M+SG%(^M=M?A?F28/TZKSH= MI.QVBDMH]0NQTYDA69KM2TQUBE5VDDC(H%R+J9.PZGR1(%M8T:B3Z/931R7> M99/\2N59I(VZ"U'_6MVQBA-*&X>L+'1>?\]2>6Y)[E'*@\UUBJ$\S22(%\.T M]6N\>,9)5G,NV%D_X8J33\H!M! D;$+SS)^'RC=-*;+6&)WG3DFIITF9D%03 M/,7LV:F\@[@)ZF1O2LG$9J#._)F_0R5_XTUI/.BU[HI)+V')\Y C6IKO8FGD M8=U#3\^UY:SK$=VMT.@[*BI#&P6.M5Y0Q-/-NR9>]ZBD[77^1\,?29H!G.G//=Y\9L98GQI1!51P:[\[X MQ>=+F-IQ<89&WT!1 $3HDE/FW0:( /658?$D MH:5?VZVETIB5T,_[=NM'&1X3NOGP0S>Y:)S03&M]X.KP7ZJ>7UOK$JM#C4(M M+?>(U>%-H9S6^L5R,%6HH[7N<#&0*U326A^X)( L]-):1U@5LQ9*::W?6Q4I M%\IIK=.[/2XO5-1:W[<8_QKGK)0ZA%BY>;[K[,;VX4 M"<3F3"_Y(W[)ZX]6[N\VIB\R?]TQ>9/\K!0 38 \ !X96YE+65X.3E?,2YH=&WM6UM7VS@0?N^OT-*SVQ?L M7"'$23G+LCQT3^GV _=ISVR/8Z'RI(KR9CLK]^1G?10"!!N!1+SD,1H+,TW M\WEF)$OCU&9B]PT;I\!C^F9CBU; [L$7;SCT.^-6?4D"K9G$.%3QE!D[%?!^ M(^-Z@C)@O+#J%\QRI2V7=I3S.$8Y"=A.?C[:J+J-\>S[32B]%'"2VJ#M#U"2 MQ#B?-R9*6L_@?Q!TVKD=U0-X5N5!>U2U)3Q#,0U., /#/D')CE3&Y5PP5-:J MC&0MG%N/"YS(0$!BW1B839C1T?L-^M'9&?;;G?Z@]V_;/\TG&XP+N[AAIE>) ML4U)IQXAFBG?Z70K>+^][6RW1^-6OCMN$M%) G2Z7!PGF*( MEM5D<3WL.D,\M0GF+KUH@>LQ/PSBW+T_#=Q"_]Z"KGL9W;M]ZBS4^&[3<&D\ M QJ3EP-QD?^69?!B;^YIY.):@(=<1RD;;+)NN]M?89SLE3V#-Z-92$O+0P'S M\4*E8]#5@"[?D'ZNU1-\J@I+O9U#/*I[[G?]]J^CF3RY0/#<0& @YYI;J),4 M=:[G/9^AH< FT$Z#N?1,B*3BRUF!NB9+M&Q<=].R^G)_\YPQ( LLM%))JGFA M!OXUJ#X]]X\%0YZ!MAAQ,?,"N?!GY<_[D'@I/^^)D$!Q=@Q1H=$B*;:OL@R- M024ON'\9 W>[_G#KV6R\?5N.>48K_^%,:U(RK2BR$!_'W)V!WV[,O9A7C3,.W HQEB589LRDP'JHS\#*2I4<>8A)P$V0J5!A%@0+T M)BN!E2XFN_MC*CF 4>'"5%+=GE#=H4Q<.=YZN+MP>^+W^X(?2\*I0K^MO;_66 MKA_[?J>I(*\PXD_RE>-\5M,_6)1?5]P$?Q426/_*#'?)(J[[?$7BBYFM"U8+(/$A*,2(2I M4E(%F&+.8K"@Z8ZZD'3,:^AV9[H]X^K2R[7IA44.-]NQ@F8[-*=9WX3IEGKH M&:OF8.:N)!OZO89D2Y.,$F=#L:8F>PR3?JB695C&:8(O)RQ $5TSJ424^% MIV[9A5K"R^EU'0GX237%VF/2KD0A6,ZGU73@>JX1/:F,)>X]*P,(XOM5%F\=E[/$H F,J/FJ8$-M 4\Y%>0;&JB;H-91[4LJYE-O0 M[KZTZS>T6VC'RTRC%,HM4H*M5T4BFF&X[+J6)&OM/>+&A,[.\^S.N,\;Q9.4 MRZ_NW>OF"K^M7N4W\2W38B><%.)LGY\6E#)6&.PJ.W)MG'@,$JG(.0)1)9YJ M@?Z02SX!O<*H#[X5*-$B.]'D7[L#?T MAMM;PQ7&>N"6SX)9-/9G#_+O,'.\'ZGL:<%W?+?&=,$ 3@%,I@_=D_2@\R(7 MCC\E LZ]>FG1K=M$;CNN',5H XML 15 xene-20240308_htm.xml IDEA: XBRL DOCUMENT 0001582313 2024-03-08 2024-03-08 0001582313 false 8-K 2024-03-08 XENON PHARMACEUTICALS INC. Z4 001-36687 98-0661854 200-3650 Gilmore Way Burnaby BC CA V5G 4W8 604 484-3300 false false false false Common Shares, without par value XENE NASDAQ false